Differentially expressed LncRNAs as potential prognostic biomarkers for glioblastoma

Shao, Mengmeng; Liu, Wenyun; Wang, Yu

doi:10.1016/j.cancergen.2018.05.001

Cited by 9 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More and more evidence have suggested that lncRNAs could be novel biomarkers for diagnosis and treatment of various diseases [37][38][39][40]. Yu et al reported that lncRNA MALAT1 may increase cardiomyocyte autophagy and myocardial injury during I/R by negatively regulating miR-204 expression [20].…”

Section: R E T R a C T E Dmentioning

confidence: 99%

RETRACTED ARTICLE: LncRNA TUG1 protects against cardiomyocyte ischaemia reperfusion injury by inhibiting HMGB1

Shi

Dong

Gao

2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The aim of this study was to investigate whether lncRNA TUG1 could mediate the progression of ischemia-reperfusion injury following acute myocardial infraction. Mouse cardiomyocytes HL-1 cells were subjected to oxygen glucose deprivation followed by reperfusion (OGD/R) to induce myocardial I/R injury. The expression of TUG1 was detected by real-time PCR. Overexpression or down expression of TUG1 was performed in mouse HL-1 cardiomyocytes. The myocardial cell viability and apoptosis were respectively detected. In addition, the expression levels of inflammatory factors, apoptosis-related proteins and HMGB1 proteins were detected. Besides, an inhibitor of HMGB1 was used to treat cells to verify the relationship between TUG1 and HMGB1 protein. The expression of TUG1 was significantly up-regulated in OGD/R-induced myocardial HL-1 cells. The overexpression of TUG1-induced inflammation and apoptosis in OGD-R-induced myocardial HL-1 cells. Knock down of TUG1 protected OGD/Rinduced myocardial I/R injury by inhibiting HMGB1 expression. Suppression of lncRNA TUG1 may prevent myocardial I/R injury following acute myocardial infarction via inhibiting HMGB1 expression.

show abstract

Section: R E T R a C T E Dmentioning

confidence: 99%

RETRACTED ARTICLE: LncRNA TUG1 protects against cardiomyocyte ischaemia reperfusion injury by inhibiting HMGB1

Shi

Dong

Gao

2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Dysregulated transcripts including mRNAs, microRNAs (miRNAs), lncRNAs, and circular RNAs (circRNAs) can be a primary feature in human cancers [4][5][6][7][8][9][10][11][12][13]. With the rapid development of high-throughput RNA sequencing and the wide application of bioinformatics, lncRNAs, as one subset of ncRNAs with the length >200 nucleotides, were identified to participate in diverse biological processes in cancer [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway

Niu

Zhang

et al. 2020

Oncogene

View full text Add to dashboard Cite

Glioma is the most common malignant tumor in the central nervous system. Altered long noncoding RNAs (lncRNAs) are playing regulatory roles in physiological and pathogenic processes in cancer. Here, we uncovered a differentially expressed lncRNA called brain cytoplasmic RNA 1 (BCYRN1), and elucidated its function and molecular mechanism in the progression and development of glioma. Three fresh tumor tissues from glioma patients and three normal brain tissues from craniocerebral trauma patients were prepared for high-throughput RNA sequencing. Differential RNA transcripts and BCYRN1 were identified by RT-qPCR in glioma samples and controls. CCK-8, colony formation assays, flow cytometry, TUNEL assays, cell migration assays, wound-healing assays, and xenograft model were established to investigate the biological function of BCYRN1 both in vitro and in vivo. Various bioinformatics analysis, dual-luciferase reporter assays, biotinylated RNA pulldown assays, and rescue experiments were conducted to reveal the underlying mechanisms of competitive endogenous RNAs (ceRNAs). 183 lncRNAs were identified with significant dysregulation in glioma and randomly selected differential RNAs were further confirmed by RT-qPCR. Among them, BCYRN1 was the most downregulated lncRNA, and its low expression positively correlated with glioma progression. Functionally, BCYRN1 overexpression inhibited cell proliferation, migration in glioma cell lines, whereas BCYRN1 depletion resulted in the opposite way. MiR-619-5p was further confirmed as the direct target of BCYRN1. Mechanistically, miR-619-5p specifically targeted the CUE domain containing protein 2 (CUEDC2), and BCYRN1/miR-619-5p suppressed glioma tumorigenesis by inactivating PTEN/AKT/p21 pathway in a CUEDC2-dependent manner. Overall, our data presented that the reduced expression of BCYRN1 was associated with poor patient outcome in glioma. BCYRN1 functioned as a ceRNA to inhibit glioma progression by sponging miR-619-5p to regulate CUEDC2 expression and PTEN/AKT/p21 pathway. Our results indicated that BCYRN1 exerted tumor suppressor potential and might be a candidate in the diagnosis and treatment of glioma.

show abstract

“…Furthermore, the expression of the PBX1 gene has been linked to acute lymphoblastic leukemia. The RTN1 gene is also linked to childhood leukemia 28 , and it is thought to be a particular marker for cancer and neurological illness detection, as well as a possible molecular target for treatment 29,30 . The finding that PBX1 and RTN1 have an impact on these disorders suggests that the two genes may potentially have a function in AML.…”

Section: Discussionmentioning

confidence: 99%

Ensembling Deep Learning and Bioinformatics for Precision Treatment Recommendations: Application in Acute Myeloid Leukemia

Meng

Wang

Guo

et al. 2022

Preprint

View full text Add to dashboard Cite

The most common kind of acute leukemia, acute myeloid leukemia (AML), has poor clinical outcomes and inadequate therapy. Although there are many therapies for AML, AML patients still have low 5-year overall survival rates. This study aimed to identify key genes and pathways of AML, to predict the prognosis of AML patients, A total of 133 upregulated DEGs and 15 downregulated DEGs were identified. They were enriched in protein binding, insulin secretion regulation, and cancer transcriptional misregulation. The module analysis of the PPI network of DEGs identified ten genes (PCLO, SYT1, STXBP1, GPHN, SYNCRIP, PFN2, ENAH, PAIP1, HNRNPD, STXBP5). SYT1 and PCLO were overexpressed in AML patients and have great potential as prognostic factors and therapeutic targets for AML. Further, by Deep learning, we combined other factors, including age, gender, past malignancy, and prior therapy, to inference whether patients will survive within 6 years by deep learning, the (Ctd)-index was greater than 80%, which indicates DeepHit model can reliably predict the prognosis of AML patients.

show abstract

Differentially expressed LncRNAs as potential prognostic biomarkers for glioblastoma

Cited by 9 publications

References 14 publications

RETRACTED ARTICLE: LncRNA TUG1 protects against cardiomyocyte ischaemia reperfusion injury by inhibiting HMGB1

RETRACTED ARTICLE: LncRNA TUG1 protects against cardiomyocyte ischaemia reperfusion injury by inhibiting HMGB1

LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway

Ensembling Deep Learning and Bioinformatics for Precision Treatment Recommendations: Application in Acute Myeloid Leukemia

Contact Info

Product

Resources

About